Stem Cell Therapy: A Game-Changer for Brain Injury Recovery

Stem cell therapy restores hope for Tennessee woman with brain injury

Concussions and brain injuries have long plagued athletes, accident victims, and everyday individuals, often resulting in long-term disabilities and diminished quality of life. However, a promising new treatment—stem cell therapy—may offer a revolutionary path to recovery. One recent case sheds light on the potential of this therapy to restore hope and function for those suffering […]

Sernova FDA Clearance: Cell Pouch for Hypothyroidism Treatment

Sernova FDA Clearance: Cell Pouch for Hypothyroidism Treatment

Sernova Biotherapeutics has received FDA clearance for its Investigational New Drug (IND) application.  This clearance allows them to evaluate their Cell Pouch bio-hybrid organ, combined with autograft thyroid cells, in patients with hypothyroidism undergoing thyroid surgery.  The Cell Pouch aims to restore natural thyroid function, eliminating the need for hormone replacement therapy.  Preclinical studies showed […]

Celularity and BlueSphere Bio Collaborate on Cell Therapy Manufacturing

Celularity and BlueSphere Bio Collaborate on Cell Therapy Manufacturing

Celularity Inc., a cellular medicine company, has entered into a collaboration agreement with BlueSphere Bio (BSB).? Celularity will leverage its manufacturing capabilities to produce BSB’s T cell receptor (TCR) T cell therapies.? This partnership will focus on manufacturing and quality control at Celularity’s New Jersey facility for BSB’s therapies, including a treatment for Acute Myelogenous […]

Longeveron: WHO Approves “Laromestrocel” for Lomecel-Bâ„¢ Stem Cell Therapy

Longeveron: WHO Approves "Laromestrocel" for Lomecel-B? Stem Cell Therapy

Longeveron Inc. announced that the World Health Organization (WHO) has approved the International Non-proprietary Name (INN) “laromestrocel” for their cellular therapy Lomecel-Bâ„¢? Lomecel-Bâ„¢ is being evaluated as a treatment for Alzheimer?s disease and hypoplastic left heart syndrome (HLHS).? It is a proprietary product made from medicinal signaling cells and has received FDA designations such as […]

GATC Health’s Stem Cell Therapy for Diabetes

GATC Health's Stem Cell Therapy for Diabetes

GATC Health Corp. announced a groundbreaking stem cell therapy for diabetes, detailed in a recent publication in the American Journal of Biomedical Science & Research. This autologous therapy uses a patient’s own stem cells to potentially treat both Type 1 and Type 2 diabetes, offering improved blood sugar control and reduced medication dependence. The process is […]

Adia Nutrition Enters Global Stem Cell Market – New Clinic in Winter Park, FL

Adia Nutrition Enters Global Stem Cell Market

Adia Nutrition, a publicly traded company, has opened a Florida clinic, Adia Med, offering stem cell treatments using ethically sourced umbilical cord stem cells. This clinic aims to provide convenient and FDA-compliant stem cell therapies, comparable to international clinics, for various conditions. The company highlights the quality of its stem cells, the convenience of a […]

NYSCF and Janssen Partner on Neurodegenerative Disease Drug Discovery

NYSCF and Janssen Partner on Neurodegenerative Disease Drug Discovery

The New York Stem Cell Foundation Research Institute (NYSCF) and Janssen Research & Development, a Johnson & Johnson company, have partnered to accelerate the development of precision medicines for neurodegenerative diseases.  NYSCF’s AI-powered platform, using automated stem cell systems, will be leveraged to identify new drug targets and therapies. This collaboration combines NYSCF’s expertise in stem cell […]

BioCentriq Expands Cell Therapy Manufacturing

BioCentriq Expands Cell Therapy Manufacturing

This exciting news in the cell therapy sector could revolutionize how quickly life-changing therapies reach patients. BioCentriq, a leading cell therapy contract development and manufacturing organization (CDMO), is set to expand its operations and establish a cutting-edge cell therapy manufacturing facility in Princeton, New Jersey. This facility will become BioCentriq’s new headquarters, marking a significant […]

Promising Phase 1 Results for Hemophilia A Gene Therapy

Promising Phase 1 Results for Hemophilia A Gene Therapy

Expression Therapeutics announced promising Phase 1 clinical trial results for its novel gene therapy, ET3, treating hemophilia A. The trial, detailed in the New England Journal of Medicine, showed significant increases in Factor VIII levels and a reduction in bleeding events in participants with severe hemophilia A. The therapy uses a lentiviral vector targeting hematopoietic stem […]